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Abstract 
The interactions between multiple drugs administered to an organism concurrently, 
whether in the form of synergy or antagonism, are of clinical relevance. Moreover, un-
derstanding the mechanisms and nature of drug-drug interactions is of great practical 
and theoretical interest. Work has previously been done on gene-gene and gene-drug 
interactions, but the prediction and rationalization of drug-drug interactions from this 
data is not straightforward. We present a strategy for attacking this problem and produc-
ing a computational solution. Our approach makes use of published work on large-scale 
genetic, chemogenomic and drug-drug interactions in order to find compound pairs that 
are likely to interact synergistically or antagonistically with each other in S. cerevisiae. 
We defined gene sets whose heterozygous deletion confers sensitivity to a drug as ‘drug 
target candidates.’ For each drug pair whose interaction is known in S. cerevisiae, we 
found the number of genetic interactions between each drug’s ‘target candidates.’ We 
examined whether genetic interaction frequency between ‘drug target candidates’ is dif-
ferent than overall genetic interaction frequency. We attempted to use this as a basis for 
prediction of drug-drug interactions, and experimentally tested some of the interactions. 
Additionally, we have also analyzed the DrugBank database of drug-drug interactions. 
DrugBank includes data about the interactions of clinically used drugs in human pa-
tients, which is supplied in natural language format. We have standardized this data by a 
process of manual curation, and produced a large dataset of machine-readable human 
drug-drug interaction data. We also present some analyses performed on this dataset.  
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Özet 
Bir organizmaya uygulanan farklı ilaçların beraber kullanıldıklarında gösterdikleri 
etkileşimler, gerek sinerji gerek antagonizm şeklinde, klinik önem taşımaktadır. Ayrıca, 
ilaç-ilaç etkileşimlerinin mekanizmasını ve doğasını anlamak büyük hem pratik hem de 
teorik açıdan önemlidir. Daha önce ilaç-ilaç ve gen-ilaç etkileşimleri üzerinde çalışılmış 
olsa da, bu verilerden ilaç-ilaç etkileşimlerinin tahmini ve rasyonalizasyonu karmaşık 
bir problem oluşturmaktadır. Projemizde bu problemin işlemli olarak çözülmesi için bir 
strateji sunuyoruz. Kullandığımız yöntem yayınlanmış, büyük çaplı genetik, 
kemogenomic ve ilaç-ilaç etkileşimi verilerini kullanarak S. cerevisiae’da sinerjistik ya 
da antagonistik etkileşimler yapma ihtimali yüksek olan bileşik çiftleri bulmaktadır. 
İlaçlar için, heterozigot delesyonları ilaca duyarlılık yaratan genleri ‘hedef adayları’ 
olarak tanımladık. İlaç çiftlerinin ‘hedef adayları’ arasındaki genetik etkileşimlerin 
sıklığına bakarak, bunu genel genetik etkileşim sıklığı ile karşılaştırdık. Bunu temel 
alarak bilinmeyen ilaç çiftlerinin etkileşimini tahmin etmeye çalıştık ve bazı tahminleri 
deneysel olarak kontrol ettik. 
Ayrıca, DrugBank veritabanında bulunan ilaç-ilaç etkileşimlerini analize ettik. 
DrugBank insanlarda klinik olarak kullanılan ilaçların etkileşimlerinin doğal dil olarak 
içermektedir. Bu verileri elle kategorize ve standardize ederek bilgisayarla okunabilen 
bir formata çevirdik. Bu verilerin de analizini sunuyoruz. 
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Chapter 1: Prediction of Drug-Drug Interactions 
1. Introduction and Background 
This section provides an overview of the various sources of data used in this research 
project, as well as the species of yeast with which experiments were conducted.  
1.1. Saccharomyces cerevisiae 
Saccharomyces cerevisiae, also known as baker’s yeast or budding yeast, is a well-
known species of yeast which has been used in various industries (such as brewing and 
baking) for centuries. It is also one of the most commonly used model organisms in bi-
ology. 
It is a unicellular eukaryotic organism, which has a doubling time of 1-2 hours [1] [2]. It 
can be easily cultured in the laboratory with standard culture media such as YPD [3]. 
This makes it a very convenient organism for studying drug interactions, making it a 
popular choice in many studies. 
1.2. Chemogenomics 
The field of chemogenomics encompasses the study of chemicals and their effect on an 
organism in the context of its genome. With chemogenomics, the emphasis is placed on 
considering the response of the genome as a whole in order to understand the effects of 
a chemical [4]. Among other things, chemogenomics offers the promise of resolving the 
targets of drugs which cannot be adequately studied with conventional approaches due 
to their action involving the participation of many genes in the genome [5]. 
In particular, an important study by Hillenmeyer and colleagues in 2008 bears relevance 
for our research. In this study, a large variety of conditions (which included many small 
molecules in addition to nutrient deficient media and different temperature levels) is 
applied to yeast (S. cerevisiae) deletion libraries in order to generate chemogenomic 
profiles, which quantify the role of the genes in the yeast genome. 
The Hillenmeyer study employs two kinds of yeast deletion libraries for separate sets of 
experiments. There is a set of 5985 heterozygous deletion strains and another set of 
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4770 homozygous deletion strains. Every deletion strains correspond to yeast lineage 
with a single open reading frame (ORF) removed from its genome. The strains are iden-
tified by the gene which was deleted. 
In either case, in order to conduct the chemogenomic profiling experiments, all of the 
deletion strains (heterozygous or homozygous) yeast strains in a library (heterozygous 
or homozygous) are pooled together, and grown for 24 hours in culture medium under 
the condition being tested (e.g. in presence of a drug). A control experiment is per-
formed by growing the pool of strains in a normal yeast culture medium without impos-
ing additional conditions. 
All of the deletion strains were constructed in a specific manner, such that a unique, 
specific 20 base pair sequence of DNA is inserted into the genome of each strain during 
the deletion process. This short sequence serves as a barcode that can be used to identify 
individual strains [4] [6] [7] [8]. When the experimental condition is applied, the growth 
rate and fitness of each individual strain is altered in some way, presumably relating to 
the particular gene deleted from it. At the end of the 24 hour culture period, the relative 
populations of different deletion mutants can be compared to the control experiment, in 
order to determine which strains have benefited from the condition and which have be-
come less fit [4]. Statistical analysis is performed on numbers of deletion strains under 
each condition and the end result is a series of z-scores, indicating how the fitness of the 
strain has been perturbed in that particular condition in multiples of the sample standard 
deviation. [4] There are certain important differences in the interpretation of results for 
experiments with homozygous and heterozygous deletion libraries. 
With homozygous deletion libraries, the assay is referred to as “homozygous profiling” 
(HOP). The gene in each strain is removed entirely, so that the gene is completely non-
functional in the mutant [9]. The consequence is that if a condition, or commonly a drug, 
exerts its influence on the yeast cell by interacting with the product of this gene in some 
fashion, then it will no longer be able to exert this influence on the deletion mutant, 
which lacks this target gene. As such, genes which correspond to strains that have be-
come enriched after growing in a condition are thought to be targeted by that condition 
[4]. Ordinarily, the yeast cannot survive the complete removal of any gene. 19% of all 
yeast genes lead to lethality when removed, another 15% lead to a serious growth defect 
– the so called essential genes [10] [11] [12]. The Hillenmeyer study itself demonstrated 
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that for 97% of genes at least one environment exists which makes them essential, even 
if they are not essential in the standard culture conditions [4]. This is part of the reason 
why the homozygous deletion library is smaller than heterozygous. 
With heterozygous deletion libraries, the assay is called “haploinsufficiency profiling” 
(HOP). In this case, only one of the two copies of a gene is deleted to construct the dele-
tion mutant strain. Therefore, the gene is still active, but may be active at a lower activi-
ty level [9]. In this case, it is thought that any condition which affects the yeast by im-
pairing the function of the deleted gene will be more effective, since the strain has been 
sensitized to it by virtue of a lower gene product level [4]. Deletion mutants which are 
most strongly affected by the condition relative to control will therefore correspond to 
genes most critical for the response to that condition. 
1.3. Gene-Gene Interactions 
As said above, 19% of the genes in the yeast genome are necessary for survival in 
standard culture conditions. The remaining genes, when deleted singly, do not preclude 
the yeast’s survival. But when two genes are deleted in the same strain, various effects 
such as growth defects can emerge, which are referred to as genetic interactions [13]. 
The BioGRID is an online database which stores and makes available physical (protein) 
and genetic interactions from different species [14], including S. cerevisiae. Yeast ge-
netic interactions account for the largest group of interactions listed, making up 74% of 
all genetic interactions [14]. 
A 2010 study by Costanzo and colleagues [15] is worth discussing here. The Costanzo 
study is the largest contributor of interactions to the BioGRID S. cerevisiae genetic in-
teraction database, it currently makes up 34% of these genetic interactions. As part of 
this study, a synthetic genetic array [8] was used to create a large number of double mu-
tants (which have deletions in two genes); in total 5.4 million pairs of genes were 
probed. 
Once constructed, these double mutants are cultured and the colony size is tracked [16]. 
After analysis, the data quantifies how fitness has been affected by combining two gene 
deletions in a single strain. Costanzo and colleagues present a scoring system for meas-
uring the strength of a genetic interaction in terms of the fitness perturbation. These 
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scores are also available on the BioGRID, however, not all BioGRID interactions have a 
score since some contributing studies are qualitative in nature. 
1.4. Drug Interactions 
By analogy to epistatic interactions, it is possible to speak of the interactions between 
individual drugs [17]. Pairs of drugs used concurrently may be thought of as behaving 
antagonistically, synergistically depending on how much stronger or weaker the out-
come is compared to what would be expected from considering the individual effects of 
each drug. The case where the outcome coincides with the expectation of observing a 
sum of individual effects, the drugs are considered to not interact, and are said to be in-
dependent or additive. 
In principle, it is possible to speak of drug effectiveness in terms of any number of giv-
en phenotypic changes, not all of which are practical or expedient to measure. Com-
monly, in order to measure drug effectiveness, growth rate is used. A study which gath-
ered detailed data on mRNA levels during a number of drug interaction experiments, 
and concluded that about 70% of the variation is explained by a parameter correspond-
ing to growth [18]. Therefore, growth appears to be the single most important factor 
with regard to drug combination treatments; moreover, growth also has immediate clin-
ical relevance. 
While it is generally understood that drug antagonism represents a decrease of the effect, 
and synergy represents an increase, the exact details of the definition of interaction are 
consequent on the method of measurement used to detect it. 
Bliss independence [19] is one of the simpler methods, although it is widely used [20] 
[21]. With Bliss independence, the inhibition caused by individual drugs is measured as 
a fraction of the negative control. If after using drug A,    of the cells continue to grow, 
and after using drug B,    of the cells continue to grow, then it is expected that when 
these drugs are used together is       of the cells will continue to grow (a smaller num-
ber than either    or    since typically these are between 0 and 1). 
An issue with Bliss independence is that it does not take into account the concentrations 
of the drugs. Even in absence of any interaction, a nonlinear increase in inhibition may 
take place, simply because the act of combining the drugs has also increased drug dos-
age [17]. 
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Another method, Loewe additivity [22], alleviates the issue of changing concentrations. 
With Loewe, the baseline of independence is defined in terms of self-self interactions: 
A drug is assumed to not interact with itself. Therefore, if     and     are the concentra-
tions of drugs A and B respectively, this pair of drugs is independent if       
(   )    remains constant for different values of  . In other words, on a two dimen-
sional representation of the drug gradients, straight lines of constant inhibitions connect 
equivalent (in multiples of MIC, the minimum inhibitory concentration) drug dosages. 
Outcomes above or below this baseline are taken as synergistic or antagonistic. This 
manifests itself as a “bending” of the isoboles outward or inward towards the origin 
point (representing the control case where no drug is added). A recent study by Cokol 
and colleagues [23] has implemented a version of the Loewe model in order to quantify 
drug-drug interactions in a number of experiments. 
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2. Motivation and Contribution of the Thesis 
Our original intention was to ascertain whether it is possible to predict the interactions 
between pairs of drugs in the yeast Saccharomyces cerevisiae based on information re-
garding the effects of the individual drugs and the known data regarding the functional 
genomics of this organism. More specifically, we have attempted to utilize two datasets: 
 The chemogenomic profile dataset published by Hillenmeyer and colleagues as 
accompaniment to their 2008 study [4], which is primarily used in order to pre-
pare lists of “candidate targets”, which are genes that appear to have been im-
portant in how the organism responds to a drug. 
 The database of genetic interaction data provided by BioGRID. 
In addition to these, a set of data with drug pair whose interaction status was previously 
tested and thus is known, has been used for purposes of calibration and testing of our 
algorithms. 
The first of our inputs, namely the lists of candidate drug targets, is fundamentally easi-
er to generate quickly, as for   drugs there need to be   experiments. The second input 
of genetic interaction data differs in this regard, in that for   genes, a number of indi-
vidual tests on the order of    must be performed. However, efficient methods exist for 
rapid, high throughput querying of genetic interactions. Moreover, the number of genes 
in an organism tends to be limited (Saccharomyces cerevisiae has close to 6000 ORFs 
[24]) further bounding the problem size. And lastly, at this time, a non-trivial fraction of 
this space has already been explored: BioGRID lists close to 198000 genetic interac-
tions. 
Neither of these applies to the task of mapping out drug-drug interactions. The problem 
of finding the interactions between   drugs scales with   , and the individual experi-
ments are far more laborious and error-prone than genetic interaction experiments; dos-
age of the drug also becomes a more significant issue as opposed to the binary nature of 
gene knockout studies. The number of chemicals that exists is either unbounded or at 
least very large, and very few of their combinations (especially in a comparative sense) 
have been tested. Of those studies which have tested them, substantial heterogeneity 
exists to the point where data from different studies may be incompatible. 
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Therefore, the ability of somehow inferring in silico whether a given pair drugs will in-
teract based on these other more readily available datasets represents a substantial gain 
in terms of work required to obtain the valuable data of drug combination effectiveness. 
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3. Methods and Materials 
3.1. Candidate Drug Target Assignment 
In order to calculate correspondence scores, it is necessary to have a list of so called 
“candidate targets” for each drug. Phenomenologically speaking, the candidate targets 
of a drug are those genes whose deletion strains resulted in the most statistically signifi-
cant perturbation in survival during competitive growth experiments under the influence 
of that drug. The implicit assumption our method carries is that such genes, which when 
absent greatly alter the susceptibility of the yeast cell to the drug, are most important for 
the action of the drug. 
We have defined the methods of assignment of such candidate drugs targets on a drug-
by-drug basis. In other words, from one chemogenomic profile corresponding to one 
drug, it is possible to play any of several methods which we describe below, to extract 
in each case a set of genes which are the candidate targets. Provided a set of such targets 
is available for either drug in a pair, these sets are later used to calculate the correspond-
ence score of the pair. 
The methods we defined were as follows: 
 Rank method: Top   strains were taken as targets for each profile, with the same 
  for all drugs. 
 Cutoff method: Strains above or below a given z-score threshold were taken as 
targets for each profile, with constant threshold across drugs. 
 Inflection method: An attempt is made to determine the point where the distribu-
tion of genes z-scores changes, and z-scores above this point are taken as targets. 
 Best replicate method: Similar to the cutoff method, but instead of combining 
the replicates with Stouffer’s method, the replicates were combined by taking 
the maximum or minimum score recorded for each given strain and drug. 
 HOP method: For each drug, the targets were assigned to be those genes for 
which the genetic interaction vector has a Spearman correlation coefficient [25] 
of at least   vs. the discretized chemogenomic profile. 
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Of these, the first three operate with combined heterozygous (HIP) profiles. The fourth 
method, as noted, operates with non-combined HIP profiles. The last method operates 
on combined homozygous (HOP) profiles. 
For each of the five methods we attempted, there was one free variable which behaved 
similar to a threshold, and had to be optimized. This is referred to in this text as the “pa-
rameter” of that method. The selection of an appropriate value for this parameter is de-
scribed elsewhere, in 3.5.1. Calibration of algorithm parameters. The different methods 
are summarized in Table 3.  
3.1.1. Fitness score combination 
In the Hillenmeyer dataset, it was often the case that conditions had been repeated, be-
cause more than one experiment was conducted for each condition. For our purposes, 
we required exactly one chemogenomic profile for each unique condition, so for those 
conditions where more than one profile existed, we combined all the replicates to obtain 
a consensus profile. 
Since the Hillenmeyer dataset provides both p-value and z-score profiles for each exper-
iment, it is possible to combine each of those. For combining   p-values   , a method 
published by Fisher [26] can be used: 
     ∑   (  )
 
 
Which gives a chi-square statistic corresponding to the combined p-value, with    de-
grees of freedom. 
For the combination of   z-scores   , a method was presented by Stouffer [27]: 
  
∑    
√ 
 
Which gives the combined Z-score for the set of replicates. 
3.2. Construction of a Gene-Gene Interaction Network 
I order to construct a gene-gene interaction matrix; we have used the database of S. 
cerevisiae genetic interactions in the BioGRID [14]. The database contains a mixture of 
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physical (protein-protein) and genetic interactions. The latter were the group that was 
pertinent to our purposes. 
Both physical and genetic interactions in the BioGRID are further labeled by the class 
of experiment conducted to detect them. Among genetic interactions, not all classes 
were equally well represented. Therefore, we designated certain classes as our accepted 
positive and negative genetic interactions. The basis for selection was mostly preva-
lence – we ignored classes which were very few in number. The classes of negative and 
positive genetic interactions included are given in Table 1. 
 
Negative Positive Not included 
   
Negative Genetic Dosage Rescue Dosage growth defect 
Synthetic Growth Defect Phenotypic Suppression Dosage lethality 
Synthetic Lethality Positive Genetic Phenotypic enhancement 
 Synthetic Rescue Synthetic haploinsufficiency 
Table 1: Classes of BioGRID genetic interactions selected to include in our analysis 
(left two columns) and the classes which were excluded (rightmost column). 
 
The BioGRID data identifies gene pairs as ordered pairs, so the format of the data al-
lows for directionality of the individual interactions. Reasoning that genetic interactions 
are inherently non-directional (in other words, the distinction between an interaction of 
gene A with gene B vs. the interaction of gene B with gene A was not considered bio-
logically meaningful) and that the data on directionality is more to do with the experi-
mental setup rather than the underlying biology, we discarded the information regarding 
this directionality in the gene-gene interaction network we constructed. 
Lastly, the list of S. cerevisiae genes is subject to revision as new data becomes availa-
ble. Therefore, some new genes may be added or some old ones may be removed as 
time passes. In our case, since we intended to combine the gene-gene interaction matrix 
with the target lists obtained from the chemogenomic data of Hillenmeyer et al., a fur-
ther question of compatibility arose since not only did the Hillenmeyer study use a list 
of genes that was valid at the time of the study and since had been revised, but they also 
did not possess deletion mutant strains for every gene thought to exist in the S. cere-
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visiae genome at the time. The Hillenmeyer dataset identifies genes primarily by their 
ORFs, and we have therefore regarded data concerning only those genes the ORFs of 
which have been mentioned both in the Hillenmeyer and the latest published list of 
genes from SGD [24]. 
At the end of the procedure, we generated three square binary matrices: One for genetic 
interactions we took as negative, one for genetic interactions we took as positive, and 
one with the two matrices combined. For each such matrix   , we set      if an 
interaction of gene   with gene   or of gene   with gene   belonging to a relevant class of 
interactions (listed in Table 1) has been recorded in the BioGRID. Detection of a genet-
ic interaction in a single experiment was therefore sufficient for us to include it in our 
data. For the matrix containing both negative and positive genetic interactions, the pres-
ence of an interaction belonging to a class of either the negative or positive genetic in-
teraction classes from Table 1 was sufficient. 
We also ignored self-self interactions, meaning the data where the interaction of gene   
with gene   is recorded. The diagonals of our genetic interaction matrices, correspond-
ing to such self-self interactions, were therefore composed solely of zeros. 
3.3. Evaluation of Drug-Drug Interaction 
We based our method of evaluating drug-drug interaction based on the method de-
scribed in [23]. Briefly, we calculated alpha scores measuring the interaction and then 
classified scores within a range as drug synergy, drug antagonism, or independence. 
For the results of drug-drug interaction experiments conducted in the original Cokol 
2011 publication, which served as the training data, the alpha scores were already given 
in the supplemental information of the paper. For the thresholds, we have used the 
thresholds originally given in the publication. Specifically, drug interaction experiment 
outcomes where         were considered synergistic, experiments where        
were considered antagonistic, and values between these two boundaries (        
    ) were considered independent [23]. 
For our own experiments, we used the same method of evaluating the isobole length, 
but adapted it to work with 4-by-4 matrices (where the Cokol 2011 publication used 8-
by-8 matrices). As input, the algorithm is given a series of optical density measurements 
over time for each well in the experiment, with different wells corresponding to differ-
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ent drug concentration combinations. Each well’s measurements are then collapsed into 
a single score (by getting the area under the growth curve) and the matrix of growth 
scores is normalized. On the normalized matrix, the amount of the “bend” of the longest 
contour line is quantified with a logit function and returned as the   score. The   score 
is expected to be below 0 for synergistic interactions (where the contour lines bend to-
wards the well with no drug applied) and above 0 (where the contour lines bend in the 
other direction). Values close to 0, indicating independence, are expected when the con-
tour line is a straight line connecting the two corners of the matrix. For details, see Al-
gorithm 1. 
3.4. Calculation of Gene-to-Drug Correspondence Scores 
Our intention was to determine whether it is possible to infer drug-drug interactions 
based on examination of the (a) “candidate drug target” lists derived from chemoge-
nomics data, and (b) a gene-gene interaction network. 
We also possessed a set of data for some drug-pairs, which were experimentally ob-
tained from a previous study. These may be regarded as the desired outputs of our own 
computational work, and as such, can be used for verification of the method ultimately 
employed. 
Thus, in order to link the two input datasets together, we have developed a computa-
tional approach which considers drugs in pairs, and calculates a numerical metric which 
can be taken as a quantification of the likelihood that these two drugs will interact. In 
this text, for the sake of convenience, this metric will be referred to as the “gene to drug 
correspondence score”. 
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Algorithm 1: Alpha score calculation [23] 
Input: 
  : A 4-by-4-by-96 matrix     where each element shows the  th optical densi-
ty reading of the yeast culture growing in the  th well of the  th row on the mul-
ti-well culture plate, with       representing the measurements from the well 
where no drug was applied. 
Output: A number ( ) quantifying the interaction between the two drugs assayed in this 
experiment. 
1. Create a new matrix     (∑      )      (             ) to represent 
the growth scores. 
2. Create a new matrix              to represent the normalized growth. 
3. Find the number       (           )  representing the larger of the two cor-
ners of the matrix where the maximum amount of the single drug was applied. 
4. Define a sequence            . 
5. Obtain the contour line for each    where      and    , represented as a se-
ries of line segments. 
6. Select the longest contiguous line, generating two vectors   and   describing the 
respective coordinates of each point along this line. 
7. Create a new vector        (
  
    
)     (
  
    
). 
8. Return         (  ). 
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In order to calculate this correspondence score, we began with the initial assumption 
that the number of genetic interactions between genes targeted by drugs which them-
selves interact must be higher. The basis of this approach consists of the following: 
Both a genetic knockout (which participates in genetic interaction events) and direct or 
indirect chemical inhibition of a gene product must have the same effect, the blocking 
of gene action. In the first case, the gene action is blocked because there is no gene to 
exert its effect, and in the second, the gene action is blocked because the gene product is 
chemically prevented from exerting its function. Indeed, the possibility of such a “cor-
respondence” between the effects of gene knockouts and drugs has attracted the atten-
tion of researchers [28] [29] [30] [31]. In our case, we hypothesized that pairs of drugs 
which interact must interact because in fact, each drug is blocking actions of genes 
which in turn themselves interact. 
The generation of candidate target lists is described elsewhere (see section 3.1. Candi-
date Drug Target Assignment), and these lists are taken as inputs by the correspondence 
calculator algorithm. Given a set of genes for either drug (referred to as   and   in Al-
gorithm 2), as a first step, genes which are in both sets are removed (this amounts to 
taking the set difference in either direction, producing what is referred to in Algorithm 2 
as    and   ). In our current implementations and given the present data, no gene is con-
sidered to interact with itself in any case, but removing shared targets obviates the need 
for that consideration and produces more salient data. 
The remaining targets are thus unique for each drug within that pair. Therefore, by ne-
cessity the genetic interaction graph between them can only be a bipartite graph, with 
each drug’s targets confined to their own part. From this, the maximum possible number 
of edges (representing genetic interaction) can be calculated as the product of the num-
bers of nodes on either side, or the cardinalities of the two sets. This number, referred to 
as  , is an upper bound. The actual number of edges can be counted by querying of the 
gene-gene network that we have produced (described in section 3.2. Construction of a 
Gene-Gene Interaction Network). This is the number  . 
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Algorithm 2: Calculation of correspondence score 
Inputs: 
  ,  : Two lists of candidate targets for two drugs. 
  : A genetic interaction matrix where       if genes   and   interact and 0 
otherwise. 
Output: A correspondence score   showing the prevalence of genetic interactions be-
tween the candidate targets of the two drugs. 
1. Generate unique target lists    and   : 
a.        (    denotes the set difference of   and  ) 
b.        
2. Calculate the potential interactions            . 
3. If     return    . 
4. Initialize    . 
5. For each   from 1 to      do: 
a. For each   from 1 to      do: 
i.     
  
ii.     
  
iii. If       increment   by 1. 
6. Return      . 
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An obvious measure, which we have elected to employ, is to compare   and   in terms 
of their proportion. This proportion, with a provision to account for the undefined case 
of 0 divided by 0, is called the correspondence score. Following the logic of our initial 
hypothesis of gene-drug correspondence, we expect that this “correspondence score”, 
which is unique to each drug pair, shall have some sort of relation to the interaction sta-
tus (whether measured in binary, ternary or continuous variable fashion) of that pair 
which may be exploited in order to predict the interaction status from the correspond-
ence score alone. The formula we have used was: 
               {
       
     
 
The provision for the case of     (which would otherwise generate an undefined cor-
respondence score) notably includes: 
 Self-self drug interactions (where a drug’s interaction with itself is measured) 
 Interactions of different drugs which happen to have identical lists of candidate 
targets 
 Interactions of different drugs where the candidate targets of one drug are a 
strict superset of the other candidate targets of the other drug 
According to our hypothesis, in all of these cases we would not predict any interaction 
to occur based on our concept of correspondence, further justifying the use of a corre-
spondence score of 0 for such cases. 
3.5. Predictions 
We were able to calculate correspondence and make predictions from different sets of 
inputs: With the gene-gene interaction matrix, it is possible to use only negative genetic 
interactions, only positive genetic interactions, or both. Likewise, it is possible to con-
sider drug interactions in terms of synergy vs. no synergy, antagonism vs. no antago-
nism, and independence vs. interaction. Furthermore, with the candidate target lists, it is 
possible to generate the lists of targets for each drug with different methods. A list of 
the variants we have used is given in Table 2. 
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However, in each case, the inputs are: 
 A binary matrix showing which genes are known to interact with each other 
 A set of vectors listing the candidate targets of each drug 
 A mapping of drug pair to binary value showing whether the drugs in this pair 
are taken to interact or not 
Though we were able to measure the performance of our prediction method across these 
different inputs, we only experimentally verified the case of predicting drug synergies 
based on negative genetic interactions. 
 
Target assignment Genetic interactions Drug-drug interactions 
   
Rank 
Negative Synergy 
Positive Antagonism 
All Any interaction 
Cutoff 
Negative Synergy 
Positive Antagonism 
All Any interaction 
Inflection 
Negative Synergy 
Positive Antagonism 
All Any interaction 
Best replicate 
Negative Synergy 
Positive Antagonism 
All Any interaction 
HOP correlation 
Negative Synergy 
Positive Antagonism 
All Any interaction 
Table 2: A list of the 15 validation runs presented in this text, according to which target 
assignment method, genetic interaction set, and drug-drug interaction set were used. 
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This section describes in detail how predictions were made and verified. To summarize: 
1. We calibrated, or trained, our algorithm on the known drug-drug pairs from the 
Cokol 2011 dataset, excluding self-self experiments, which served as our train-
ing set, in order to fine-tune it so that it was best able to detect the difference 
between the correspondence scores of interacting and non-interacting drug pairs. 
It was then possible to generate a list of correspondences for unknown drug 
pairs, and make predictions of interaction based on these. 
2. To check the performance of our algorithm for a given set of inputs, we repeat-
edly hid a subset (the “validation set”) of our known drug-drug interaction data, 
and attempted to predict them. The performance was quantified with receiver 
operating characteristic (ROC) curves. 
3. To experimentally verify the predictions, we again trained the algorithm on the 
entire set of known drug-drug interactions we had available, generated corre-
spondence scores for all possible pairings of the 343 conditions included in the 
Hillenmeyer study. We selected a correspondence threshold based on the ROC 
curve and predicted the drug pairs above this as interacting and the ones below 
it as non-interacting. Out of this large number of predictions, we selected 12 
drugs and experimentally tested their combinations for interaction. 
 
3.5.1. Calibration of algorithm parameters 
Each of our methods for candidate drug target assignment was devised such that there 
was one crucial free variable, which is referred to as the “parameter” of that method. 
However, calibration was necessary to ascertain the value of that parameter which pro-
vides the best prediction performance. For instance, if candidate drug targets are taken 
to be   most affected deletion strains for a drug, then there remains the task of finding 
an appropriate value of  . 
To attack the problem of selecting an appropriate parameter for each given method, we 
defined a range containing the probable values of the parameter, made repeated sam-
plings within this range, and selected the one among them which afforded the most pre-
dictive power. The exact ranges we have used are given in Table 3. 
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Method Parameter represents Range 
   
Rank Number of targets per drug              
Cutoff Z-score threshold for targets                 
Inflection Threshold for differential of z-
score across genes 
                          
Best replicate Z-score threshold for targets, rep-
licates combined by taking the 
maximum of all experiments 
                
HOP correlation Correlation of chemogenomic 
profile to the genetic interaction 
matrix column 
                     
Table 3: Ranges of parameters scanned for every target assignment method. 
 
For each given possible value of the parameter, we first divided our training data into 
lists of drug pairs which were classed as interacting or non-interacting. We then calcu-
lated the correspondence scores for each of these pairs. As our hypothesis relied on the 
correspondence scores of one class being more likely to be larger than the other, we 
used the MATLAB implementation of the Wilcoxon Rank Sum test [32] [33] (equiva-
lent to the Mann-Whitney U test, see Algorithm 3) to calculate a p-value corresponding 
to the degree to which the correspondence scores of the two classes were distinct. The 
parameter which resulted in the smallest p-value was then assigned as the appropriate 
value for that set of inputs and candidate drug target assignment method. 
For a flowchart describing the overall process of parameter calibration see Figure 1. 
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Algorithm 3: Mann-Whitney U test [34] 
Inputs: 
 Sets    and   containing the observations for two variables. 
Output: A p-value corresponding to the likelihood that the two variables come from the 
same statistical distribution. 
1. Calculate the   statistic by combining the two sets of observation and count the 
number of times an observation from   is preceded by an observation from  . 
2. Calculate   
      
 
 where     and     are the number of elements in   and   re-
spectively. 
3. Calculate   √
      (         )
  
. 
4. Calculate   
   
 
. 
5. Return the p-value corresponding to the z-statistic from a standard normal distri-
bution. 
  
21 
 
 
Figure 1: A diagram illustrating the overall process of calibrating the prediction algo-
rithm. The drug pairs in training set are separated into interacting and non-interacting 
and a Mann-Whitney test is performed to obtain a p-value measuring the likelihood of 
the two groups being distinct. This is repeated for every value of the parameter that was 
selected for testing. In the resulting plot of p-values for various values of the parameter, 
the parameter with the best p-value is chosen as the optimal parameter for that combina-
tion of inputs. The predictive power of is further described by an ROC curve. 
 
3.5.2. Validation with training data 
In order to obtain a better idea of what the performance of the prediction algorithm is 
likely to be with a given configuration of inputs, we attempted to create average ROC 
curves from repeated runs in which the algorithm attempted to predict the interaction 
status of already known drug pairs. 
To accomplish this, we sequestered a randomly selected subset of 30 drug pairs from 
our training data into the validation set. The algorithm was then trained on the remain-
ing training data, excluding these 30 validation pairs. Therefore the algorithm had no 
knowledge of these 30 points prior to prediction. We then calculated the correspondenc-
es of these 30 pairs, and compared them with the actual interaction status of each pair. 
We measured the success rate of such a prediction attempt with the area under the ROC 
curve (“area-under-curve”, or AUC – for plotting of AUC curves see Algorithm 4). This 
process was repeated 20 times, producing 20 ROC curves, producing 20 AUC values. 
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The average and standard deviation of these were taken as the “average AUC” and “er-
ror of the average AUC”, respectively. For plotting, the average AUC curve and the er-
ror bars were calculated with threshold averaging, using. 
3.5.3. Prediction of novel interacting drug pairs 
In order to predict the interaction status of unknown pairs, the algorithm was trained on 
the entire set of drug-drug interaction data we had available from the Cokol 2011 study, 
excluding self-self experiments. For gene-gene interactions, only the negative genetic 
interactions were used. For candidate drug target assignment, the top   strains method 
(with      ) was used. We classed drug-drug interactions as synergistic vs. non-
synergistic. 
After calibrating the algorithm, we calculated the correspondence for pairwise combina-
tions of all 343 conditions included in the Hillenmeyer dataset (and for which, therefore, 
a list of candidate targets could be assigned). In order to actually predict the synergies, 
we classed correspondence scores above a threshold as synergistic and the remainder as 
non-synergistic. For the value of this threshold, we chose the correspondence value 
which corresponded to the point on the ROC curve closest to the top-left corner, which 
was 0.0072192. 
Among the multitude of predictions thus generated, we selected 54 pairs among 12 
drugs (not including the self-self pairings, which our algorithm ignored during training 
and prediction). The drugs were selected (Table 6) after considering different factors 
such as obtaining a balance of both positive and negative predictions, selecting drugs 
which were easy to obtain and affordable, and safety of the chemicals. 
All the interactions among these 12 drugs including the self-self pairings (which served 
as controls) were experimentally verified by us.  
 
  
23 
 
Algorithm 4: Plotting of the receiver operating characteristic (ROC) curve [35] 
Inputs: 
   : A vector showing the score for the  th event 
   : A binary vector showing the actual outcome for the  th event, with 0 showing 
negative and 1 showing positive outcome 
Output: A vector of points (   ) describing the ROC curve, which can be plotted in two 
dimensions to produce the ROC plot. 
1. Create vector    holding the elements of    but sorted in ascending order. 
2. Generate a sequence  :  
a. For each     (where   is the number of elements in  ),    
       
 
. 
b.    is set to a number lesser than all elements of  . 
c.    is set to a number greater than all elements of  . 
3. Calculate the sequences    ,    ,    ,     for each   (    indicates number of 
elements in set  ): 
a.     |{ |     }          | 
b.                          
c.                          
d.                          
4. Calculate for each  : 
a.    
   
       
. 
b.    
   
       
. 
5. Return (  ,   ) for every  .  
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Algorithm 5: Threshold averaging of multiple ROC curves [35] 
Inputs: 
        : Two matrices containing, respectively, the x and y-coordinates of the  th 
point on the  th ROC curve. 
Output: Two vectors  ̅  and  ̅  containing, respectively, the x and y-coordinates of the 
average ROC curve as well as two vectors    and    containing, respectively, the square 
root of the variance of the x and y-coordinates of point  . 
1. For each  : 
a. Set  ̅      (           ). 
b. Set  ̅      (           ). 
c. Set    √   ({   |     }). 
d. Set    √   ({   |     }). 
2. Return  ̅ ,  ̅ ,    and   . 
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4. Results and Discussion 
4.1. Interaction prediction 
4.1.1. Genetic interaction matrix 
In the entire BioGRID database (version 3.2.99) there were 322349 total interactions, 
including physical and genetic. Genetic interactions made up 197634 of these, or 61.3%. 
We used only the genetic interactions. A breakdown of the count of different interaction 
listings recorded in the database can be seen in Table 4. 
Of these genetic interactions, 147028, or 45.6% of all genetic interactions, fell under the 
categories we defined as “negative”. The largest sub-category of these were interactions 
specifically marked as “negative genetic” (74.0%), but synthetic growth defect and syn-
thetic lethality interactions were also fairly sized groups (15% and 11% respectively). 
The groups we classed as positive genetic interactions amounted to 39828 (12.4% of all 
genetic interactions) in aggregate. Interactions marked “positive genetic” were more 
than half of this group (58.6%), with dosage rescue, phenotypic suppression and syn-
thetic rescue making up the rest in roughly similar proportions (12.9%, 14% and 15% 
respectively). 
Our definitions of positive and negative interactions did not cover all classes, so some 
types of interaction reports were consequently ignored by our analysis. Collectively, we 
ignored 10578 interactions, or 5.4% of all genetic interactions. This comparatively 
small group included interaction types which were too few in number or too ambiguous 
for our purposes. 
We observed two kinds of irregularities in the BioGRID database: Firstly, the database 
is structured such that a query gene and an interaction partner gene are defined for each 
interaction. For an interaction between genes A and B, potentially there will be another 
interaction between B and A (due to the manner in which researchers submit their data 
to the BioGRID, this is may not necessarily be the case, however). 
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Class Number 
Percent 
(of total) 
Percent 
(of superset) 
    
Physical interactions 124715 38.7% 38.7% 
Genetic interactions 197634 61.3% 61.3% 
    
 Positive 39828 12.4% 20.2% 
  Dosage rescue 5152 1.6% 12.9% 
  Phenotypic suppression 5587 1.7% 14.0% 
  Positive genetic 23332 7.2% 58.6% 
  Synthetic rescue 5957 1.8% 15.0% 
    
 Negative 147028 45.6% 74.4% 
  Negative genetic 108809 33.8% 74.0% 
  Synthetic growth defect 22046 6.8% 15.0% 
  Synthetic lethality 16173 5.0% 11.0% 
    
 Excluded 10578 3.3% 5.4% 
  Dosage growth defect 1921 0.6% 18.2% 
  Dosage lethality 1603 0.5% 15.2% 
  Phenotypic enhancement 6771 2.1% 64.0% 
  Synthetic haploinsufficiency 283 0.1% 2.7% 
    
Total 322349 100% - 
Table 4: Counts of genetic interaction entries that were present in the raw BioGRID da-
tabase for Saccharomyces cerevisiae, version 3.2.99. 
 
There were 120509 cases such that a genetic interaction was recorded between A and B, 
but there was no corresponding interaction recorded between B and A (although in 
some of these). We assumed that these were sufficient evidence, reasoning that genetic 
interactions are reciprocal in nature and that there is no reason to expect that an interac-
tion will no longer be observed if the subject and query genes were swapped. 
Secondly, we observed 18 genetic interactions where the systematic names of both in-
teracting genes were exactly the same, such that these implied the gene was interacting 
with itself. These entries did not all come from the same study, but some were submit-
ted by different studies. Our algorithm for constructing the gene-gene interaction matrix 
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from BioGRID ignored self-self interactions, so these 18 entries were skipped at that 
stage, but even if that were not the case the correspondence score algorithm would not 
include self-self genetic interactions in the calculation since it builds lists of unique po-
tential interactors. Because of this, and their very small number, we did not investigate 
these apparent self-self entries further. 
Our final negative genetic interaction matrix contained 101955 interacting pairs be-
tween 5025 genes. The positive genetic interaction matrix contained 27048 pairs be-
tween the same genes. The combined (positive and negative) genetic interaction matrix 
contained, as would be expected, their sum of 129003 interacting pairs.  These numbers 
are substantially lower than the numbers of genetic interactions we observed in the Bi-
oGRID. Part of the reason is the high amount of redundancy: The counts we gave in 
Table 4 are numbers of entries in BioGRID. For a given pair of genes (A, B), there 
could be more than one interaction entry for (A, B) and for (B, A), but all of these 
would be recorded as a single pair in our constructed matrices, since we are interested in 
whether any interaction (meeting our criteria) at all has been observed between two 
genes. 
Furthermore, BioGRID references a total of 5782 genes, while we confined our analysis 
to a list of 5025. Interactions involving 757 genes were therefore present in the Bi-
oGRID but were ignored by us since we did not have sufficient data (e.g. chemoge-
nomics) to include them in correspondence calculations. 
 
Matrix Interacting pairs Genes 
   
Negative genetic interactions 101955 5025 
Positive genetic interactions 27048 5025 
All genetic interactions 129003 5025 
Table 5: A breakdown of the number of interacting gene pairs and the number of S. 
cerevisiae genes taken into account by our analyses. 
 
28 
 
4.1.2. Validation 
We have made several validation runs for various combinations of inputs. In every case, 
30 of 119 known drug-drug interaction pairs were hidden, and predicted after training 
on the remaining 89. The process was repeated 20 times. 
Each run produced a single calibration curve of p-value vs. parameter, used to select the 
best parameter. As a representative example, the calibration curves of the negative ge-
netic interaction, rank method, synergy prediction case (which is also the one we exam-
ined experimentally) are given in Figure 2. According to these, it appears that a number 
of sweetspots exist for optimal prediction of synergies: It’s possible to obtain good per-
formance if each drug is assigned about 30, 230, 370 and 480 genes as candidate targets. 
It is also possible that higher numbers could provide good performance, but the task of 
scanning different parameter values is computationally expensive and we did not query 
those possibilities. 
Each calibration curve therefore reveals which numbers of targets for a drug are appro-
priate, at least for prediction of drug interactions.  The shape of a calibration curve per 
se does not appear to have any obvious pattern, and it is likely that a multitude of com-
plex factors influences it, since it is ultimately a consequence of the genomic landscape 
of the organism. However, it is remarkable that although in terms of magnitude there is 
a fair degree of variation across different training data sets, the overall shape remains 
fairly robust: The sequence of peaks and valleys is reproduced consistently across dif-
ferent runs, even though a slightly different set of training data is used in every case. 
From this, it is possible to make the deduction that the calibration curves are specific to 
the genome (or more precisely the genetic interaction network) of an organism and as 
such, closely related species which have similar drug interactions should generate simi-
lar curves. Unfortunately, we did not have opportunity to test this notion. 
Figure 2 gives the calibration curves pertaining to only one configuration of inputs. In 
total, there were 15 such validation processes, each consisting of 20 runs. Detailed plots 
for the remainder are not reproduced here for the sake of brevity. 
Lastly, if one consults the actual p-values of the curves, it can be observed that in many 
cases the p-value falls below the p=0.05 mark (or about -1.3 on the base 10 logarithmic 
scale) which ordinarily indicates statistical significance. However, as the curves are not 
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adjusted for multiple hypothesis testing, it is likely not correct to draw such a conclu-
sion.  
 
 
Figure 2: Calibration curves for 20 validation runs, each representing an attempt to train 
on 87 known pairs. Targets were selected using the rank method, which assigns the top 
  strains as candidate targets for a drug (x-axis). Negative genetic interactions only 
were used for correspondence calculations. Every line represents one run. The vertical 
axis shows the logarithm (base 10) of the Mann-Whitney U test p-value for a difference 
of distribution between the correspondence scores of synergistic drug pairs vs. non-
synergistic pairs. 
 
In each run, the algorithm used the calibration curve to pick the best parameter which 
optimized the target assignment scheme, and generate an ROC curve for the prediction 
of the 30 hidden known pairs which represented performance had that optimal target 
assignment method been used. Since we performed 20 runs, 20 such curves were gener-
ated, and they were averaged to obtain an estimate of the overall performance for a giv-
en configuration of prediction bases (such as the selection of genetic interactions, and 
types drug interactions to be predicted, as well as target assignment scheme). A repre-
sentative ROC curve is given in Figure 3, which is also the ROC curve corresponding to 
the configuration we tested experimentally. 
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The ROC curve shows that in general, this particular method produced performance 
slightly better than a random guess. It also appeared that the performance was compara-
tively better when a lack of false negatives was valued more than a lack of false positive. 
Intuitively, a positive in our setup represents an interaction between to drugs (whether 
defined as synergy, antagonism, or either) while a negative is the lack of such an inter-
action. A true positive or true negative would be a drug pair correctly predicted by the 
algorithm. A false positive would be a pair predicted to interact, which did not turn out 
to interact in reality. A false negative is a pair which interacts, but was not predicted to 
interact. 
In drug-drug interaction experiments, a crucial difficulty is the large number of potential 
pairs that need to be tested for interaction, which renders a brute-force approach imprac-
tical; every experiment represents non-trivial expenditure of material cost and labor. 
Therefore, in addition to prediction per se, it is also valuable to be able to simply filter 
out pairs which are unlikely to interact and thus could be excluded from an experi-
mental interaction screen, increasing interaction hit rate and reducing the per-
experiment expense. 
In our case, such an “elimination of unlikely pairs” relates to true negative and false 
negative rates. Specifically, the critical number is the false negative rate, which repre-
sents the number of drug pairs the algorithm would wrongly prescribe the exclusion of. 
Therefore, to an experiment designer interested in eliminating low-value experiments 
(i.e. drug combinations unlikely to be found to interact even if tested); a low number of 
false negatives is of particular value. For our algorithm, the optimal tradeoff between 
false positives and false negatives is a smaller number of the latter, at the expense of the 
former, suggesting its suitability for such a pre-screening purpose. 
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Figure 3: Representative ROC curve, showing the actual average ROC curve for the 
case where negative genetic interactions were used with the rank method to predict drug 
synergies. Each blue curve shows the ROC curve of individual validation runs (there are 
20 in total but many overlap). The green line shows the random-guess baseline. The red 
curve tracks the average of all 20 ROC curves, and the grey lines show 1 standard devi-
ation, representing the error, at each point. 
 
In all, we conducted 15 different validations, 3 for every target assignment method: One 
to predict synergy using negative genetic interactions, one to predict antagonism from 
positive genetic interactions, and one to predict either kind of interaction from all genet-
ic interactions. The area under curve (AUC) metrics summarizing each such validation 
are given in Figure 4. As the error bars indicate, in many cases there was not sufficient 
ground to believe that on average the prediction scheme would fall above the random 
guess line a significant fraction of the time, even though the mean was above the ran-
dom guess threshold, however prediction of synergies from negative genetic interac-
tions was the exception to this, possibly due to larger amount, completeness and quality 
of data for both genetic interactions and drug synergies. 
Most often, combining synergies with antagonism and negative genetic interactions 
with positive reduces predictive power, as would be expected since combining interac-
tions in this manner removes the distinction between positive and negative outcome 
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from a given interaction. But interestingly, when targets were assigned such that genes 
were assumed to be targeted by a drug if their deletion produced a similar effect to that 
of the drug (as measured by correlation between the homozygous deletion chemoge-
nomic profile and the genetic interaction vector of a gene) then combining positive with 
negative genetic interactions and grouping together synergies with antagonisms (there-
fore discriminating only interaction vs. no interaction for drug-drug pairs) the mean per-
formance appeared to be better than both synergies with negative interactions and an-
tagonisms with positive genetic interactions.  
The HOP method uses data qualitatively different from the haploinsufficiency profiling 
(HIP) data used by the other 4 methods [4]. With HOP experiments, genes are com-
pletely deleted from each strain, so the expectation is that strains corresponding to genes 
targeted by the drug (the outcome of drug action being reduced growth of the strain) 
will have better fitness in presence of the drug compared to control. The deletion is ex-
pected to render a strain resistant to the drug which targets the deleted gene. With HIP 
experiments, only one copy of the gene is deleted, so it is expected that deletion strains 
will become more susceptible to the drug and grow less in its presence. This difference 
could be responsible of the different behavior of our HOP target assignment method 
compared to the others. 
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Figure 4: Comparison of prediction performance of various prediction methods as 
measured by area under curve (AUC) of the ROC curve. Filled circles show mean AUC 
over 20 validation runs and vertical bars show 95% confidence interval (1.96 standard 
deviations) for the mean. Cyan bars show the performance when synergy is predicted 
using negative genetic interactions, purple shows prediction of antagonism from posi-
tive genetic interactions, purple shows prediction of all drug-drug interactions from all 
genetic interactions. Green line shows the AUC for random guessing. Horizontal axis 
labels show target assignment method: Rank,   targets per drug. Cutoff, targets above 
determined by a z-score threshold. Inflection, targets determined by second differential 
of z-score vs. genes. Cutoff, best, similar to cutoff method but replicate experiments are 
combined by taking the maximum instead of using the Stouffer method. HOP, targets 
are assigned on basis of high correlation between the chemogenomic profile and the ge-
netic interaction vector of a gene. 
 
4.1.3. Predictions 
For predictions of unknown pairs, we have elected to use negative genetic interactions 
only to predict synergies vs. non-synergistic pairs, using the rank method to assign tar-
gets. 
During the training phase, the calibration curve given in Figure 5 was produced. Ac-
cording to this, the best parameter for target selection was determined to be       
targets for each drug. 
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Figure 5: Parameter response curve for the final prediction run. Rank method was used 
with negative genetic interactions to predict synergies vs. non-synergies.  
 
The ROC curve for the 119 known drugs is given in Figure 6. The area under the curve 
was 0.71. It can be seen that the curve resembles the average curve from the validation 
runs given in Figure 3 and that the AUC is slightly higher than the mean AUC given in 
Figure 4. This is the expected outcome, since the validation sets used to calculate aver-
age AUC were smaller, thus there was less training data and mean prediction perfor-
mance should have been slightly smaller than in this final run of predicting unknown 
pairs. 
Based on the ROC curve, the best prediction threshold was found to be 0.0072, meaning 
that optimal prediction performance would result if correspondence scores above this 
were predicted synergistic and those below it were predicted non-synergistic. 
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Figure 6: ROC curve for the algorithm after calibrating and training on the entire avail-
able dataset of known drug-drug interactions. Green line represents the random guess. 
Blue circle shows the cut-off point which results in the ROC value closest to the top left 
corner. 
 
There were a total of 343 conditions given in the Hillenmeyer dataset, and we calculated 
correspondence scores for each non self-self combination. This generated a total of 
(   
 
)  
       
 
       correspondence scores. 
Figure 7 shows the histogram of all correspondence scores thus calculated. The shape of 
the curve clearly does not constitute a normal distribution, as measured by the Lilliefors 
test of normality [36] (the p-value for rejecting the hypothesis that the distribution is 
normal was less than     ).  
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Figure 7: Histogram of correspondence scores calculated for unknown condition pairs 
covered in the Hillenmeyer dataset, calculated using only negative genetic interactions, 
and distinguishing only synergies from non-synergies, using the rank target assignment 
method with 225 targets per drug. 
 
Figure 8 shows a histogram of the base 10 logarithm scores. These were also not normal, 
as calculated by the Lilliefors test (      ). Although the normal fit appears to fol-
low the data closely, some irregularities and asymmetry is still present even after taking 
the logarithm. 
4.1.4. Experimental verification 
For experimental verification, we selected 12 drugs from the Hillenmeyer dataset (see 
Table 6), and took their correspondence scores (calculated as described in the previous 
section) to represent predictions. This comprised a total of 66 unique non-self pair cor-
respondence scores. 12 more correspondence scores for self-self pairings were assumed 
to be 0 as per the definition of the correspondence score. 
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Figure 8: Histogram of the base 10 logarithm of correspondence scores calculated for 
unknown condition pairs covered in the Hillenmeyer dataset, calculated using only neg-
ative genetic interactions, and distinguishing only synergies from non-synergies, using 
the rank target assignment method with 225 targets per drug. Red line shows normal fit. 
 
 
18N 1,8-nonadiene 
57D chloroxine 
5CQ cloxyquin 
ALV alverine citrate 
BEN benomyl 
BPA bisphenol 
DRO drofenine hydrochloride 
FLA flufenamic acid 
FNP fenoprofen 
RAP rapamycin 
SUL sulconazole nitrate 
TUN tunicamycin 
Table 6: List of drugs that were experimentally verified and their abbreviations. 
 
The correspondence scores calculated for the pairings of these drugs were evenly dis-
tributed across the typical range of all correlations. A matrix showing an overview of 
the scores is given in Figure 9. 
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Figure 9: A matrix showing the correspondence score calculated for every pairings of 
12 experimentally tested drugs. The matrix is redundant, in reality pairs are unordered 
and thus the two triangular parts above and below the diagonal are only mirror images 
of each other. 
 
Upon conducting the drug-drug interaction experiments for all of these pairs, we calcu-
lated the alpha scores for each of them to determine the interaction status. The growth 
scores resulting from the experiment are shown in Figure 10. 
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Figure 10: Growth matrices showing the growth for individual drug concentration com-
binations for tested drug pairs. Colour shows normalized growth score, measured as ar-
ea under the growth curve. Each 4-by-4 matrix has a concentration gradient of two 
drugs, one along the horizontal and one along the diagonal. For either drug, experiment 
was set up such that the bottom left corner contains no drug, while the top row (for ver-
tical drug) and right column (for horizontal drug) contain approximately the minimum 
inhibitory concentration (MIC) of the respective drug. 
 
We calculated the alpha scores for each of the 4-by-4 growth score matrices as de-
scribed in the Methods and Materials section. The alpha scores obtained in this way 
(Figure 11). 
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Figure 11: Alpha scores, quantifying the interaction status, of empirically tested drug 
pairs. Colour shows the alpha score. Values close to 0 (white) indicate independence, 
low, negative values (green) indicate synergy, high, positive values (red) indicate an-
tagonism. The matrix is redundant, only one alpha score was calculated for each unique 
pair, therefore the two triangular parts above and below the diagonal are mirror images. 
 
Although our initial calculations appeared to indicate that a fair prediction success rate 
could be expected, we did not observe a strong relation between the alpha scores and 
the correspondence scores. Figure 12 shows a plot of alpha and correspondence scores. 
Self-self pairs are included in this plot and show up as a column to the left, because they 
are automatically assigned a correspondence score of 0. The two variables appear to 
have varied in a manner largely independent of each other, contrary to what we had ex-
pected. The Pearson correlation coefficient was -0.053, and the Spearman correlation 
coefficient was -0.069, indicating almost no relation in either case. It should be noted 
that because synergy is defined to be a negative alpha score, a very good prediction 
would performance would generate a strong anticorrelation, so in this case, correlation 
coefficients closer to negative 1 indicate a better performance. 
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Figure 12: Scatter plot showing alpha score obtained from experiments (vertical axis) vs. 
calculated correspondence score (horizontal axis). Vertical line shows the threshold of 
0.0072, which was expected to be the optimal correspondence threshold for predicting 
synergy vs. non-synergy. Horizontal lines show the thresholds of         and 
       for synergy (negative values) and antagonism (high, positive values) given by 
the 2011 study by Cokol and colleagues [23]. 
 
For prediction, our strategy was to separate drug pairs by correspondence scores into 
pairs predicted to be synergistic, or not synergistic (antagonistic or independent pairs). 
Thus, by comparing to the threshold of 0.0072, the correspondence score is collapsed 
into a binary prediction. Pairs with a correspondence scores above the threshold are 
predicted to be synergistic. Figure 13 shows the effectiveness of this prediction method. 
Although, as noted earlier, a very strong relationship is absent, it is nevertheless con-
spicuous that the median, 25
th
 and 75
th
 percentiles, upper and lower bounds for alpha 
scores of pairs predicted to be synergistic (i.e. predicted to have a low alpha score) were 
indeed slightly lower. However, the lower bound no longer follows this trend if the only 
outlier is not excluded. 
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Figure 13: Box plot showing the actual experimental outcome of drug pairs predicted to 
be synergistic or not synergistic (including independence and antagonism). Red lines 
show median of alpha scores in either group. Blue boxes show 25
th
 and 75
th
 percentiles. 
Black lines show the entire range of all data points in the category, with the exception of 
outliers, which are shown with red crosses. 
 
We also compared the statistical distribution of the correspondence scores within the 
two categories shown in Figure 13 (predicted to be synergistic vs. the rest). The Mann-
Whitney U test p-value corresponding to the null hypothesis of both categories coming 
from the same distribution was 0.19958. Classically, values less than 0.05 are consid-
ered significant, so the alpha scores of our predicted synergistic pairs do not differ from 
the others at a statistically significant level. 
To better compare the results with the validation runs, we constructed an ROC plot 
showing the true positive and false positive rates of prediction (Figure 14). Overall, per-
formance was poor and the AUC was only 0.51. This is in contrast to the ROC curve 
obtained after training (Figure 6), which had a much higher AUC of 0.71 and was over-
all closer to the top left corner. 
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Figure 14: ROC curve for experimentally tested predictions. Green line show random 
classifier, blue shows actual ROC curve. 
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5. Conclusions and Future Work 
In this project, we have described the implementation of a method to predict drug-drug 
interactions based on large dataset of gene-gene interactions and chemogenomic pro-
files. 
Although initial tests had shown a high ability to predict interactions based on valida-
tion with known data, we did not observe a strong predictive ability after experimentally 
testing predictions. That said, we nevertheless discovered a large number of novel drug-
drug interactions in the process. 
A clear avenue for improvement of the prediction algorithm is the refinement of the cor-
respondence calculation function. In the present project, we have only demonstrated a 
function which considers the immediate neighbors of a gene while evaluating the preva-
lence of genetic interactions. Although in this current version, genes which are 2 “hops” 
apart, and genes which are many nodes apart are both considered as not interacting, it is 
possible that genes in close proximity may be influencing each other through epistatic 
events as well. To evaluate such a possibility, a more sophisticated graph algorithm 
would be required to count the connections between the targets of respective drugs. 
In addition, we have demonstrated five methods of assigning targets to drugs in this pro-
ject, and experimentally verified only one. Improvement of these target assignment 
method would doubtless contribute to increasing performance. With the availability of a 
large gene-gene interaction network, as well as external pathway databases, it might be 
possible to employ a more comprehensive method of assigning targeted genes than can 
be done with the chemogenomic profiles alone. 
Lastly, as the datasets used for training the algorithm grow, performance is also likely to 
improve. 
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Chapter 2: Standardization of DrugBank 
1. Introduction and Background 
DrugBank [37] is database which contains extensive information regarding the nomen-
clature, ontology, chemistry, structure, function, action, pharmacology, pharmacokinet-
ics, metabolism and pharmaceutical properties of a large number of drugs, including 
clinically used, FDA-approved drugs. Information is stored in “DrugCards”, which are 
composed of over 150 fields of data pertaining to a drug. 
Among other things, DrugBank includes a list of known interaction partners of each 
drug, and a natural language description of the phenotype associated with their combi-
nation use, collated from a variety of sources. Although this information is very valua-
ble, it is recorded in natural language and is not straightforward to computationally pro-
cess.  
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2. Motivation and Contribution 
Although DrugBank contains a vast array of valuable information regarding drug-drug 
interactions, the wholesale analysis of this data is somewhat restricted because it is rec-
orded in natural language, since this presents an additional challenge of parsing the data 
prior to conducting research on it. 
In order to facilitate the study and analysis of drug-drug interactions, we have worked 
together with a number of volunteers to manually curate and standardize the interaction 
data recorded in DrugBank. We have verified the accuracy of our curation with various 
methods, and created a final dataset in which all interactions are categorized according 
to their features. The dataset we have created is substantially more straightforward to 
analyze. 
During the course of our efforts, we have also composed a hierarchical grouping of dif-
ferent phenotypes, which details their relation to each other. 
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3. Methods and Materials 
3.1. Filtering of DrugBank interactions 
As the basis of our research, we used a copy of the DrugBank database last updated on 
13 February, 2012. 
Before processing and standardizing the interaction information given in DrugBank, we 
noticed that many interaction descriptions were repeated verbatim throughout the data-
base. Since manually reviewing one of such repeated annotations is sufficient to under-
stand all of them, we were able to reduce the workload substantially by eliminating du-
plicate annotations from the corpus of data that was manually reviewed. This reduced 
the number of annotations from 21750 to 6299. 
Furthermore, we also noticed that in many cases, the interaction sentences for different 
drug pairs were syntactically identical, and the only difference was the name of the 
drugs referenced. We were then able to extract patterns from the corpus of annotations, 
which mention only anonymized placeholders for the names of drugs, and therefore 
cover a large number of annotations. The extraction of these patterns is described in de-
tail in section 3.2. Standardization of DrugBank interaction data. 
However, after extracting patterns it was further possible to eliminate duplicate patterns, 
which again reduced the number of entries due for manual review from 6299 to 1897 
annotations. 
A flowchart showing the amount of data after the two filtering steps is shown in Figure 
15. 
3.2. Standardization of DrugBank interaction data 
The annotations in DrugBank were given on a pairwise basis. For each drug, the known 
interaction partners of that drug were listed and an annotation text explaining the inter-
action was present. We elected to first manually process the annotation texts independ-
ent from their associated drugs, and then match the standardized data of each annotation 
to its relevant drug pairs. 
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Figure 15: Datasets generated at each stage. The DrugBank database we began with 
contained 21750 interaction annotations among 1114 drugs. There were 6299 total 
unique sentences (some annotation texts were repeated several times). After 
anonymizing the drug names, 1897 syntactical patterns of interaction annotation were 
obtained. These were manually classified by volunteers. 
 
In order to reduce the workload that would be needed at the manual curation stage, we 
attempted to reduce the number of annotations in DrugBank by exploiting certain com-
mon recurring patterns in the annotations. 
The process of extraction of patterns and their manual review is illustrated in Table 4. 
3.2.1. Pattern format 
In order to extract the patterns, we replaced the drug names referenced in annotation 
with the strings “Drug_1” and “Drug_2” where applicable. “Drug_1” replaced the name 
of the drug for which the annotation appeared, and “Drug_2” replaced the name of the 
drug that was given as the partner. 
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Raw DrugBank data 
Triprolidine -> Ethanol 
"Triprolidine may enhance the CNS depressant 
effects of Ethanol." 
Ethanol -> Triprolidine 
"Triprolidine may enhance the CNS depressant 
effects of Ethanol." 
Prochlorperazine -> Galantamine "Possible antagonism of action" 
Galantamine -> Prochlorperazine "Possible antagonism of action" 
Triprolidine -> Donepezil  "Possible antagonism of action" 
Donepezil -> Triptolidine "Possible antagonism of action" 
Duplicates filtered 
ID 1: "Triprolidine may enhance the CNS depressant effects of Ethanol." 
ID 2: "Possible antagonism of action" 
Anonymized 
syntactical patterns 
ID 1: "Drug_1 may enhance the CNS depressant effects of Drug_2." 
ID 2: "Possible antagonism of action" 
Manual annotations 
ID 1: "cns depressant+>" 
ID 2: "general+" 
Table 7: An example illustrating the data processing operations with representative data 
from the project. The DrugBank interaction annotations are given on a per-pair basis 
with redundancy for both directions. The same sentences or syntactical patterns are also 
often repeated. Filtering duplicates collapses duplicated sentences which arise from 
reciprocals and the same sentence being reused throughout the database. Anonymization 
of drug names further collapses sentences which are syntactically identical, and differ 
only in the names of drugs they mention. Having thus vastly reduced the number of 
sentences that must be manually curated, we instructed volunteers to assign phenotype 
tags to each pattern which uses a controlled formal grammar and vocabulary that is easy 
to parse computationally. 
 
The anonymized annotation patterns we obtained in this way were given to volunteers 
for manual review and curation. We asked the volunteers to write “tags” for each of the 
annotation patterns according to the following rules: 
 Each tag is a word or phrase representing one of the phenotypes mentioned as 
arising from the combination usage of the two drugs by the annotation pattern. 
 If more than one phenotype is described, one tag for each one is to be written. 
 For each tag, a combination of special symbols is to be included to describe 
metadata regarding the effect observed: The direction in which the phenotype 
was affected (increase, decrease), the causal relation between the effects of the 
two drugs (one drug altering the action of another, or reciprocal), and the cer-
tainty with which the interaction annotation was phrased (some annotations used 
certain wording, while others only stated the possibility of interaction). A full 
list of the symbols is given in Table 8. 
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We distributed the patterns to our volunteers in such a fashion that each pattern was as-
signed to exactly 2 different persons. The algorithm for the assignment is given in Algo-
rithm 6. 
3.3. Convergence 
After the first round of review, we evaluated the tags assigned to each sentence by using 
a metric based on the Jaccard coefficient [38] [39]. We refer to this metric as “conver-
gence”. The Jaccard coefficient measures the distance between two sets as the ratio be-
tween the number of elements in common, versus the total number of elements in the 
union of the two sets. We used a modified version of the classical definition by adding a 
provision for division by 0: 
  {
               
     
     
           
 
In our case, the two sets   and   represented the set of tags assigned by each of the two 
persons reviewing a given pattern. As a set contains only unique elements, it should be 
noted here how the equality of elements is determined. We used two definitions of 
equality: 
 Two tags are equal if the phrases used for them (ignoring the symbols) are iden-
tical strings. This is referred to as a non-strict comparison. 
 Two tags are equal if the previous, non-strict comparison holds, but also the 
symbols given for the tags are semantically equal (that is to say they convey the 
same information regardless of where in the string they occur). This is referred 
to as a strict comparison. 
After determining the convergence of all patterns, we repeatedly selected patterns with a 
convergence less than 1 and reassigned them to the volunteers. This process resulted in 
the vast majority of the patterns being reviewed with reasonable accuracy (where both 
persons reviewing it had submitted the same information). 
A small number of patterns remained at 0 convergence because the annotation text did 
not convey any useful interaction information – some annotations in DrugBank were 
composed solely of recommendations for treatment, and did not specifically state any-
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thing regarding the outcome of the combined use of the two drugs, and we ignored such 
recommendations for our analysis. 
3.4. Synonym groups 
While performing the analysis of the submissions generated by our volunteers, we no-
ticed that different phrases could sometimes be used to denote the same concept. For 
instance, synonymous words could be used to describe the same phenotype in different 
places. Additionally, our participants occasionally made misspellings and typographical 
errors, leading to an equivalent situation. This generated spurious instances of low con-
vergence, where in fact the tags submitted by either participant matched, and they had 
simply used different synonyms. 
To deal with this issue, we manually reviewed the set of all unique phrases used by the 
participants, generating a “collective vocabulary” of tag phrases. We then identified sets 
of phrases which were judged to have the same meaning, thus belonging to a “synonym 
group”. One phrase was chosen to represent each such group of synonyms, referred to 
as the canonical form. 
While calculating convergence, phrases which belonged to synonym group were first 
replaced by the canonical form, and convergence was calculated afterwards. This al-
lowed us to exclude the effects of synonyms and typographical errors from the analysis. 
3.5. Output format 
Once we had finished reviewing the patterns to a satisfactory level, they were used to 
generate the final database of standardized interactions. This took the form of a table, 
where each row contains the data for a phenotype observed between a pair of drugs, 
with columns specifying the two participating drugs, the text of the interaction the text 
of the annotation, the interaction kind, direction, and certainty.  
We generated this table in two formats, in the first all data was shown by strings. In the 
second version, every string in each column was mapped to an integer, to generate an 
entirely numerical table for better compatibility with other software. 
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Category Symbol Numerical code Meaning 
    
Interaction kind 
+ 0 Synergy 
/ 1 Additivity 
- 2 Antagonism 
? 3 Unspecified 
Certainty 
(blank) 0 Uncertain 
* 1 Certain 
Direction 
(blank) 0 Reciprocal 
> 1 Drug_1 is altering Drug_2 
< 3 Drug_2 is altering Drug_1 
Table 8: A list of symbols used to convey metadata regarding tags for DrugBank anno-
tations. There were three categories of symbols, at most one symbol from each category 
was included in the string representing each tag. The inclusion of the first category, “in-
teraction kind”, was mandatory, the other two were optional. If no symbol from a cate-
gory was found, this was interpreted as a “blank”. In versions of our data where each 
symbol was represented by a number, the numerical codes show the mapping of each 
symbol. 
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Algorithm 6: Distribution of DrugBank patterns 
Inputs: 
 A vector   containing a list of individual patterns that are to be assigned. 
 A vector   containing a list of participants who will review the patterns. 
Output: A set of vectors    where each element lists the elements of   that are assigned 
to person   . 
1.    ,    . 
2. Generate vectors   and  . For each   from 1 to     do: 
a. If      , then:           
b. If      , then:     
c.      
d.      
e. Increment   and  . 
3. Obtain a vector   by shuffling  . 
4. For each   from 1 to    : 
a.     ,      
b. Assign pattern    to participants    and   :    (     ) 
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3.6. Verification 
In order to verify the validity of our data, we distributed individual tags to a pool of 
volunteers using Algorithm 6. We developed a program which essentially displayed da-
ta pertaining to a single row of a table to the volunteers, and asked them whether the 
information was correct. A representative image of this program is shown in Figure 16. 
By looking at the patterns where both participants judged the entry to be incorrect, we 
were able to obtain a rough estimate of the correctness of the data we generated. Since 
the entire dataset was too large to verify in its entirety, we verified only a fraction of 
randomly sampled entries as a proxy for the entire set. 
 
 
Figure 16: A screen capture of the program used to verify the standardized DrugBank 
interaction data.  
 
3.7. Construction of a Phenotype Hierarchy 
With the finalized set of standardized DrugBank interaction, we reviewed the list of 
unique phrases used to describe phenotypes for relations between pairs of phrases. 
We generated a tree, rooted at the special keyword “general” (used for interaction anno-
tation where it was stated that only the “effect” of a drug is altered). Every node of this 
tree was connected to a parent which represented a phenotype thought to logically in-
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clude that node. In some cases, we added new phrases which grouped together related 
concepts, such as “Nervous system” to group together phenotypes relating to seizures, 
dopamine and serotonin imbalances, and similar effects involving the nervous system. 
This tree represented a hierarchy of phenotype descriptions, which allowed us to evalu-
ate the relations of different clusters of effects.  
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4. Results and Discussion 
4.1. Tag assignment 
We began our stage of manual review with 13 participants. 1897 patterns in total were 
distributed among them, with around 290 patterns (the numbers were not exactly equal 
since some divisions did not produce integer results) being assigned to every person. 
The number of tags assigned to each pattern by each participant is shown Figure 17. It 
can be seen that most commonly, our participants found only one phenotype for each 
pattern, slightly less commonly they found 2 phenotypes, and the number of patterns 
with larger number of phenotypes decreases progressively. A notable number of pat-
terns in each case were assigned no tags. This includes both cases where the annotation 
in truth did not contain any information relevant to our analysis, but also cases where 
the participants left the pattern blank (as we instructed them to leave blank any difficult 
patterns for later review). 
 
 
Figure 17: Histograms showing how many tags were assigned to how many patterns by 
participants at the end of the first pass of manual curation. It can be seen that the 
distribution of tag number per pattern is roughly uniform between participants. 
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Figure 18 shows the mean number of tags per pattern between all of the participants. 
This confirms what can be visually observed from Figure 17: There is an inverse rela-
tionship between the number of tags and the number of patterns such that fewer patterns 
have been found to reference a large number of phenotypes. 
It can be expected that if the case of 0 tags is excluded, the number of tags per pattern 
and the numbers of patterns will follow an exponential function such as       . The 
best exponential fit is shown in Figure 19. This function is            with an    of 
0.98 and root-mean-square error of 9.448. Although the fitted function is able to ap-
proximate the data, it follows the trend only imperfectly, as can be seen form the data-
point for 2 tags remaining above the fitted line while the remainder fall below it. 
 
 
Figure 18: Mean number of tags initially assigned to each pattern by participant. 
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Figure 19: Mean number of tags per pattern with exponential fit. 
 
The progress of convergence after successive rounds of manual review is given in Fig-
ure 20. As expected, we observed a gradual decrease in the number of patterns which 
had a convergence less than 1. After the final round of review, the vast majority of the 
patterns had a convergence of 1, and the remainder had convergence of 0, being made 
of annotations that were uninformative and therefore could not be assigned any tags. 
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Figure 20: Histogram of tag convergence over time. Convergence of each pattern as 
measured by the Jaccard similarity coefficient. Blue shows non-strict comparison and 
Red shows strict comparison. Successively darker shades show the convergence at each 
successive stage of the manual review process. 
 
4.2. Dataset characteristics 
Our final dataset detailed the interactions of 1114 drugs (of which 3 had no interaction 
phenotypes with any other drug) and as described by a total of 174 unique phenotypes. 
According to our standardization scheme, each interaction was also classified with re-
gard to the certainty of the phrasing of the annotation, whether the interaction was recip-
rocal, and the kind of interaction (increase, decrease, and so on). A breakdown of the 
number of interaction in each class is given in Table 9. 
We saw that 2756 of 14845 interactions (18.6%) were worded in certain terms. The re-
mainder used phrasing such as “possible increase of hypertensive effect” or “risk of ser-
otonin syndrome”, which implied some uncertainty regarding the interaction. 
In many cases, an annotation in DrugBank described an interaction in terms of one drug 
modifying the effect of another drug. For instance, “Drug_1 decreases the clearance of 
Drug_2” or “Drug_1 enhances the hypotensive effect of Drug_2”. Since it is stated that 
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one of the drugs is the primary agent of interaction, we recorded such instances as “di-
rectional” interactions. In other cases, when no direction was referenced, or the two 
drugs were said to affect each other (patterns such as “Drug_1 and Drug_2 increase 
each other’s efficacy”) we regarded the interaction as undirected, or reciprocal. 
Of the interactions listed in our final dataset, the majority, 8594 (57.9%) were directed. 
However, a large number, 6251 were reciprocal. 
Lastly, the third classification involved the nature of the interaction, and whether it in-
creased or decreased a phenotype. In some cases, the annotations explicitly stated that 
an interaction was synergistic or antagonistic, for these the assignment of interaction 
kind is straightforward. However, more commonly a phenotype was said to be increased 
(or amplified, enhanced, and so on) or decreased. 
When a phenotype was said to be increased, we assumed that what is meant is a syner-
gistic effect, or in other words that the increase was greater than the simple consequence 
of additivity. Synergies made up 8009 (54.0%) of the interactions. Likewise, when a 
phenotype was said to be decreased, we assumed this to mean an antagonistic interac-
tion of the two drugs. These account for another 5316 (35.8%) of the interactions. 
A minor, but fairly sizable fraction (1349, 9.1%) of annotations stated that an effect was 
additive, in these cases, we classified the interaction as additive (essentially, only sen-
tences which actually used the word “additivity” were placed in this group instead of 
synergy or antagonism). 
 
Certainty  Direction  Interaction kind 
        
Certain 2756  Directed 8594  Synergistic 8009 
Uncertain 12089  Reciprocal 6251  Antagonistic 5316 
      Additive 1349 
      Unspecified 171 
        
Total 14845  Total 14845  Total 14845 
Table 9: The numbers of entries in the final dataset belonging to various classes. 
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In addition, a small number of annotations (171, 1.2%) only mentioned that the effect 
was altered when the two drugs were used in combination, but did not specify whether 
it was increased or decreased. These were placed in the “unspecified” category. 
It is possible to regard our whole dataset as the definition of a graph in adjacency list 
format, with each edge having additional features of phenotype, certainty, direction, and 
interaction kind. If the dataset is regarded as representing a directed network, it is possi-
ble to represent both directed and reciprocal interactions as one way and two way ar-
rows. Subnetworks constructed by taking only the edges corresponding to a single inter-
action phenotype can be generated, with optional inclusion of non-certain interactions, 
with color denoting the interaction kind. 
In some cases, the analysis of both the entire network and the subnetworks was made 
substantially more involved by the additional features of directed edges. Therefore, we 
attempted to evaluate whether it was the possibility of omitting or collapsing direction.  
Figure 21 shows the 10 major contributors of directed edges. A very common type of 
interaction recorded in DrugBank was the modification in various ways of the effective 
concentration of a drug at the target site, by altering the bioavailability, absorption, 
clearance, and similar properties (these may be referred to as “pharmacokinetic” effects 
[40]). This is in line with expectations, since drugs which alter such pharmacokinetic 
properties of other drugs would lead to a directed effect: If Drug_A has some effect 
(such as decreasing blood pressure) and Drug_B alters absorption of other drugs, the 
combination would cause less Drug_A to be absorbed and the ultimate observation 
would be a lessening of the (for instance, hypotensive) effect of Drug_A while no ap-
preciable alteration of Drug_B would be observed. 
Interestingly, it appears that toxicity, anticoagulant effect, hypoglycemia, side effects 
(entries in DrugBank would often refer simply to the “side effects” or “adverse effects” 
of a drug without specifying) and sympathomimetic properties (which refers to mimick-
ing of the various neurotransmitters which are involved in the functioning of the sympa-
thetic nervous system [41] [42]) are commonly classed as directed. It is likely that the 
reason is that such effects are often modified because the function of a drug responsible 
for them is altered in a pharmacokinetic sense, such as toxicity being decreased as a 
consequence of increased clearance. 
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The biggest phenotype, “general”, includes the interactions where a general annotation 
is given stating whether the interaction is synergistic, antagonistic and so on, without 
specifying the exact phenotype. A large number interactions belong to general to begin 
with, and it is plausible that many of those would be directed. 
 
Figure 21: 10 phenotypes which contained the highest number of directed edges. In the 
legend, the numbers give the numerical ID of the phenotype in parentheses. “Others” is 
a sum of all remaining phenotypes. 
 
Figure 22 shows the phenotypes which contained the largest number of reciprocated 
edges. Notably, toxicity appears to contain a high number of reciprocated edges as well 
as directed edges, in fact, only 62% of toxicity interactions are directed. Most likely, the 
large number of interactions altering toxicity includes several different mechanisms, 
some of which are directed and some of which are not. Another phenotype which was 
also observed to have many directed edges is “general”, which, as said above, likely in-
cludes a mixture of mechanisms. Most of the other 9 major phenotypes were largely re-
ciprocal (95% or more) with the exception of hypotension (81%) and anticholinergic 
(70%). 
It can be seen that reciprocal interaction was likely for phenotypes relating to the func-
tioning of the cardiovascular system (blood pressure, heart rate, pulse) and various neu-
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rological effects. Given the large absolute and relative numbers of reciprocated interac-
tions in these phenotypes, they would be good candidates for collapsing of direction. 
Since they are already largely reciprocated, removing the directed interactions from 
them would generate an undirected network without altering the original phenotype 
subgraph significantly. 
 
 
Figure 22: Major phenotypes which have reciprocal interactions, where the combination 
phenotype is not said to have a direction or specifically alter the function of only one of 
the drugs. In the legend, numbers show numerical ID codes of the phenotype, and “Oth-
ers” is a sum of all other phenotypes. 
 
4.3. Phenotype hierarchy 
We have also provided a hierarchical tree of the phenotypes included in our data. Figure 
23 shows the topology of the phenotype hierarchy. 
We have assigned phenotype relations on the basis of inclusion, in the form of a tree. 
Every phenotype was given exactly one parent phenotype, except for “general”, which 
was the root of the tree. The intention was to assign a phenotype as a parent when the 
parent phenotype semantically “includes” it. 
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It is possible to determine relationship based on more than one basis. For instance, in 
cases where a tissue type, organ or system is mentioned, we were able to easily assign 
parents based on which organ, tissue or system was part of which. Another common 
theme was specification of a phenotype by pharmacological concepts (such as bioavail-
ability, toxicity, clearance, absorption, drug metabolism etc.) and these were grouped 
together by determining which concepts can be taken to be subclasses of the parent. 
At times, more than one parent could be assigned to a phenotype, such as for instance 
the phenotype “cardiotoxicity”, which can be thought to belong to “toxicity” as well as 
“Cardiovascular” (as it affects the heart). In such cases, we attempted to decide which 
aspect of the phenotype was more fundamental to its manifestation. For cardiotoxicity, 
for instance, the parent would be “toxicity” because cardiotoxicity is a toxicity-related 
effect, rather than a cardiovascular system effect. 
We added a number of new nodes in order to group related phenotypes as well. In total, 
18 such new nodes were introduced. They were signified by a name that starts with cap-
ital letters, unlike the normal phenotypes which are always lowercase. These newly in-
troduced nodes do not have any interactions belonging directly to them, 
Major hubs in the hierarchy tree were: 
 “Pharmacokinetics” (introduced node) – includes phenotypes such as absorption, 
bioavailability, drug metabolism and clearance. 
 “Blood” (introduced node) – includes phenotypes relating to the immune system 
(such leukopenia and immunosuppression), blood clotting and balance of ions in 
the blood. 
 “Cardiovascular” (introduced node) – includes phenotypes such as blood pres-
sure, blood vessel contraction and dilation, heart failures and arrhythmias. 
 “toxicity” – includes various toxicity effects, such as cardiotoxicity, hepatotoxi-
city, neurotoxicity and nephrotoxicity. 
 “Beneficial effect” (introduced node) – includes a number of effects which 
would generally be considered beneficial and conducive to treatment of patient. 
Included phenotypes such as antiarrhythmic effects, antiretroviral effects, con-
traception, antineoplastic effects and cardioprotective effects. 
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 “Nervous system” (introduced node) – included phenotypes such as neuromus-
cular effects, serotonin syndrome, cholinergic effects, anticholinergic effects, 
analgesia, seizures, sedation, psychosis and anorexia. 
 “Renal effects” (introduced node) – included phenotypes such as renal impair-
ment, crystalluria and diuretic effects. 
 
 
 
 
Figure 23: A graph showing the topology of our phenotype hierarchy tree. Each node 
represents one phenotype, and the colour shows the number of interactions recorded for 
that phenotype in relative terms (purple is more, green is less). The central purple note 
represents the “general” phenotype, which all other phenotypes were assumed to belong 
to. 
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4.4. Network characteristics 
In order to examine part of the interaction dataset in greater detail, we investigated the 
network properties of the whole network and subnetworks. 
For the entire network, we collapsed the initial dataset by removing phenotype data. A 
network was constructed such that two nodes (each node representing a drug) were con-
nected if there was any interaction at all recorded between them, regardless of which 
phenotype or interaction kind (meaning synergy, antagonism, additivity or unspecified 
interaction). The network was then analyzed in two ways: We considered all of the in-
teractions in the network, and only the ones marked as certain. 
The characteristics of the network are given in Table 10. We observed that in all, 1111 
drugs were involved in some sort of interactions. This is in comparison to 1114 which 
were initially present in the raw dataset – 3 drugs did have interaction annotations but 
these annotations were not found to describe any relevant interaction phenotype. Only 
710 drugs were connected to other drugs by certain interactions. 
 
 All Only certain 
   
Connected nodes 1111 710 
Directed edges 8594 1560 
Directed loops 0 0 
Two-way arrows 10721 3691 
Edges if collapsed to undirected 10865 3723 
Components (1+ nodes) 3 3 
3-cliques (communities) 11008 (6) 1226 (9) 
4-cliques (communities) 7828 (6) 349 (4) 
Biggest-clique (communities) 14: 10 (1) 6: 17 (7) 
Table 10: Network characteristics of the entire interaction network, after collapsing all 
phenotypes. The left column shows data for the whole dataset, the right column shows 
only interactions marked as certain. 
 
We observed that the 1111 drugs made up 3 connected components (such that it was 
possible to find a path between nodes within a single component, but not nodes in dif-
ferent components). Considering only the certain interactions, we saw that although 
there were much fewer edges connecting the nodes, when singleton nodes were exclud-
ed, the remaining 710 drugs still formed 3 connected components. We surmise that the-
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se 401 drugs which did not appear connected in the certain-only network were involved 
only in interactions which were recorded in an uncertain manner. 
We observed 11008 3-cliques which made up 6 communities (where a community is 
made up of overlapping cliques) in the whole network. In the certain-only network, 
there were only 1226 3-cliques and they were broken up into 9 communities. 
Similarly for 4-cliques, the whole network contained 7828 4-clique in 6 communities, 
while the certain-only network contained 349 4-cliques in 4 communities. 
4.5. Verification 
We had also conducted a verification procedure to check the accuracy of our data. In 
total, we reviewed 1050 of the interactions present in our dataset. These were distribut-
ed such that every interaction was seen by exactly two participants, and marked as cor-
rect or incorrect. 
11 interactions were marked as incorrect by both participants, and upon further review 
found to be incorrect and were rectified. This makes up 1.05% of all the interactions 
verified. The interactions were selected at random. 
Another 75 interactions (7.14%) were marked incorrect by only one participant. Upon 
further review, only 25 (2.38%) of these actually needed rectification.  
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5. Conclusions and Future Work 
We have described here the standardization of a large drug-drug interaction database 
and presented the end result. Our approach can be duplicated for other similar databases, 
and it can also be used to update the data as the contents of DrugBank itself are revised. 
The creation of a standardized, systematic dataset that is conducive to computational 
processing will, we hope, prove valuable to researcher wishing to investigate the prop-
erties of drug-drug interaction networks, especially in the context of humans, where ex-
tensive experimentation may not always be viable or practical. 
Furthermore, with a standardized version provides a foundation from which more effec-
tive record keeping practices can be established, obviating the need for further manual 
curation in future versions of this database and others. 
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